Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatment–Naive Individuals Starting Modern Therapy Combinations | Zendy

Viktor von Wyl | Zendy; Sabine Yerly | Zendy; Jürg Böni | Zendy; Cyril Shah | Zendy; Cristina Cellerai | Zendy; Thomas Klimkait | Zendy; Manuel Battegay | Zendy; Enos Bernasconi | Zendy; Matthias Cavassini | Zendy; Hansjakob Furrer | Zendy; Bernard Hirschel | Zendy; Pietro Vernazza | Zendy; Bruno Ledergerber | Zendy; Huldrych F. Günthard | Zendy

Open Access

Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatment–Naive Individuals Starting Modern Therapy Combinations

Author(s) -

Viktor von Wyl,

Sabine Yerly,

Jürg Böni,

Cyril Shah,

Cristina Cellerai,

Thomas Klimkait,

Manuel Battegay,

Enos Bernasconi,

Matthias Cavassini,

Hansjakob Furrer,

Bernard Hirschel,

Pietro Vernazza,

Bruno Ledergerber,

Huldrych F. Günthard

Publication year - 2011

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cir728

Subject(s) - efavirenz , medicine , zidovudine , lopinavir , ritonavir , hazard ratio , atazanavir , emtricitabine , drug resistance , viral load , proportional hazards model , incidence (geometry) , lamivudine , hiv drug resistance , cumulative incidence , abacavir , virology , confidence interval , cohort , human immunodeficiency virus (hiv) , antiretroviral therapy , biology , viral disease , virus , physics , optics , microbiology and biotechnology , hepatitis b virus

Estimates of drug resistance incidence to modern first-line combination antiretroviral therapies against human immunodeficiency virus (HIV) type 1 are complicated by limited availability of genotypic drug resistance tests (GRTs) and uncertain timing of resistance emergence.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research